Poseida Therapeutics’ CAR-T Programs to be Featured in Three Presentations at American Society of Hematology 2017 Annual Meeting

SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that three abstracts detailing preclinical data have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting. Data will be presented at the 2017 ASH Annual Meeting in Atlanta on December 9th and 10th. Abstracts are currently available online at http://www.hematology.org/Annual-Meeting/Abstracts/.

The following abstracts will be presented:

Presentation Title: The Application of ‘Drug-Reversible’ CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation
Abstract Number: 1893
Date and Time: 5:30 p.m.-7:30 p.m., Saturday, December 9, 2017
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Presentation Title: Production of Universal Anti-BCMA CAR-T Cells with Reduced Alloreactivity, but Potent Effector Function for the Treatment of Multiple Myeloma
Abstract Number: 503
Date and Time: 5:30 p.m., Sunday, December 10, 2017
Location: Georgia World Congress Center, Building B, Level 3, B308-B309

Presentation Title: B-Cell Maturation Antigen (BCMA)-Specific, Centyrin™-Based, PiggyBac™-Transposed CAR-T Memory Stem Cells Are Effective Against p53/- and Patient-Derived Multiple Myeloma Tumors
Abstract Number: 3068
Date and Time: 6:00 p.m.-8:00 p.m., Sunday, December 10, 2017
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

About Poseida Therapeutics, Inc.
Poseida Therapeutics is translating best-in-class gene therapy technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for cancer, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene therapy technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.

Corporate Communications Contact:
Jason Spark
Canale Communications
619-849-6005
Jason@canalecomm.com